Margarida Maia, PhD, science writer —

The U.S. Food and Drug Administration has cleared the start of clinical trial testing of KT-621, Kymera Therapeutics’ oral therapy for chronic obstructive pulmonary disease (COPD) and other diseases marked by type 2 inflammation. KT-621 is designed to target STAT6, a protein involved in type 2 inflammation, which…

The U.S. Food and Drug Administration (FDA) has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts of immune cells called eosinophils. Elevated eosinophils are a marker of type 2 inflammation, which is thought to contribute…

Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) patients with type 2 inflammation, which contributes to lung inflammation. That’s according to top-line data from a Phase 3 clinical trial called MATINEE (NCT04133909) announced by GSK…

A higher genetic risk for chronic obstructive pulmonary disease (COPD) is associated with reduced lung function starting in childhood, a study of more than 45,000 people across Europe shows. A person’s genetic makeup plays a key role in lung health early on, increasing the risk for COPD later in…

Enrollment is now complete in a clinical trial testing RejuvenAir, CSA Medical’s minimally invasive device, in adults with chronic bronchitis — one of the most common forms of chronic obstructive pulmonary disease (COPD). The trial, called SPRAY-CB (NCT03893370), enrolled 210 patients at sites across the U.S. and…

Young adults who smoke or have smoked may halve their risk of developing emphysema — a form of chronic obstructive pulmonary disease (COPD) — by eating a nutritionally rich, plant-based diet, a new U.S. study suggests. The study, “A Plant-Centered Diet is Inversely Associated With Radiographic Emphysema: Findings…

A research team at The Lundquist Institute has been awarded a four-year grant to develop a wearable biosensor that can monitor continuously the risk of acute exacerbations by analyzing the sweat of people with chronic obstructive pulmonary disease (COPD). The grant, worth more than $2.6 million, was awarded by…

People with diets rich in ultra-processed foods, those typically loaded with harmful additives and preservatives, have a 26% higher risk of dying from chronic obstructive pulmonary disease (COPD), a study drawing on U.S. data reports. Such a daily diet — one roughly consisting of more than 40% of ultra-processed…

The first patient has been dosed in a Phase 2a clinical trial testing ReAlta Life Sciences’ RLS-0071 in adults with chronic obstructive pulmonary disease (COPD) who are experiencing acute exacerbations, or sudden symptom worsening. The trial (NCT06175065) will evaluate the safety of RLS-0071 versus a placebo in…

A Phase 2a clinical trial of AstraZeneca’s experimental therapy mitiperstat is now recruiting adults with moderate to severe chronic obstructive pulmonary disease (COPD) at a study site in Choctaw, Oklahoma. The Care Access research site is among nearly 20 study centers in the U.S., located across 11…